Home / Guides / Tirzepatide brand names
Two brand names. One maker.
Tirzepatide brand name: Zepbound for weight, Mounjaro for diabetes
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
Tirzepatide’s two brand names are Zepbound, for weight loss and sleep apnea, and Mounjaro, for type 2 diabetes; Eli Lilly makes both. There’s no generic, and Zepbound costs $299 to $449 a month at LillyDirect (checked November 1, 2026). LillyDirect’s $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Compounded tirzepatide isn’t a brand, and it isn’t FDA-approved.
$139/mo on 12 months, every dosePrice Match Guarantee†
- Zepbound: weight loss and sleep apnea
- Mounjaro: type 2 diabetes
- Generic: none in the U.S.
Tirzepatide brand names
- Brand names
- Zepbound and Mounjaro
- Made by
- Eli Lilly and Company
- Zepbound is for
- Weight management, and sleep apnea in adults with obesity
- Mounjaro is for
- Type 2 diabetes in adults and children 10 and older, and lowering the risk of major heart events in adults with type 2 diabetes at high risk (label revised August 2026)
- Generic
- None approved in the U.S.
- At NexLife
- $139 a month on the 12-month plan ($169 month to month), compounded, at every dose
Not sure which one you were prescribed? Call or text
4.8 out of 5 on Trustpilot · LegitScript certified
About 3 minutes of health questions. No insurance needed.
Compounded medicines aren’t FDA-approved. A NexLife provider prescribes one only if it offers a significant difference for you compared with an FDA-approved medicine.
Brand names
Which tirzepatide brand is for weight loss, and which for diabetes?
| Zepbound | Mounjaro | |
|---|---|---|
| FDA-approved for | Chronic weight management, and moderate to severe obstructive sleep apnea in adults with obesity | Type 2 diabetes, with diet and exercise, in adults and children 10 and older (added December 2025); and lowering the risk of major heart events (cardiovascular death, heart attack or stroke) in adults with type 2 diabetes at high risk (added August 2026) |
| Made by | Eli Lilly | Eli Lilly |
| Doses | 2.5 mg to 15 mg, once a week | 2.5 mg to 15 mg, once a week |
| How it comes | Single-dose pens and vials, 4-dose vials and the 4-dose KwikPen | Single-dose pens and vials, 4-dose vials and the 4-dose KwikPen |
| Self-pay at LillyDirect | $299 to $449 a month, by dose ($449 from 7.5 mg needs a refill within 45 days; otherwise $499 to $699) | $499 a month at every dose |
Mounjaro’s approvals and forms from its FDA label, revised August 2026, and its LillyDirect price, both checked November 1, 2026. Zepbound’s price checked November 1, 2026.
NexLife Price Match Guarantee†. Already on compounded tirzepatide with another licensed provider, and paying less? We match your regular monthly price. How it works
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Tirzepatide has two brand names: Zepbound, for weight management and sleep apnea, and Mounjaro, for type 2 diabetes.
- One maker, matching doses: Eli Lilly makes both as weekly shots from 2.5 mg to 15 mg.
- Different approvals: that’s why insurers often cover one brand and not the other.
- No other version is FDA-approved. Compounded tirzepatide isn’t a brand, and Foundayo (orforglipron) is a different medicine.
- Zepbound self-pay: $299 to $449 monthly (checked November 1, 2026); $449 from 7.5 mg needs a refill within 45 days, or it’s $499 to $699.
- At NexLife, compounded tirzepatide is $139 a month on the 12-month plan or $169 month to month, at every dose.
Two brands
Are Zepbound and Mounjaro the same?
Not quite. Both are Eli Lilly’s brands of tirzepatide, weekly shots with matching dose strengths. What differs is the approval. Zepbound is approved for weight management, and for sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes in adults and children 10 and older. It’s also approved to lower the risk of major heart events in adults with type 2 diabetes at high risk (label revised August 2026). That’s why insurers often cover one and not the other.
Zepbound’s label sets out its weight-management use, with diet and exercise:
“to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised February 2026 (FDA’s copy)
Because both brands are tirzepatide, the same label says not to combine them:
“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised February 2026 (FDA’s copy)
How does one flat price compare with Zepbound and Mounjaro?
Zepbound and Mounjaro are the brand names. Here’s what a flat price looks like next to them.
- Brand prices climb. Zepbound self-pay runs $299 to $449 a month by dose; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699.
- Coverage varies. Insurers often treat Zepbound and Mounjaro differently.
- No generic version. The FDA hasn’t approved a generic version of tirzepatide.
Not a brand. A program, at one price.
- $139 a month on the 12-month plan, at every dose. Compounded tirzepatide, all in, with no membership, or $169 month to month.
- A provider who knows your history. Reviews it before anything is prescribed, and follows your dose.
- Price Match Guarantee†. Paying less with another licensed provider? We match your regular monthly price.
Real people, real answers. Not sure which tirzepatide you were prescribed? Ask us. Call or text
Check my eligibilityCompounded, not FDA-approved: a licensed provider prescribes it only when it offers a significant difference for you.
Generic
Is there a generic version of tirzepatide?
No. No generic version of tirzepatide is FDA-approved. Compounded tirzepatide isn’t a generic: a state-licensed pharmacy prepares it for one patient’s prescription, and it isn’t FDA-approved. And Foundayo (orforglipron), Lilly’s
“Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”
U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers
How the two compare on price, FDA status and fit: compounded vs. brand-name tirzepatide.
Your options
How can you get tirzepatide?
Zepbound with insurance
If your plan covers it, you pay your copay, usually after prior authorization.
Zepbound, self-pay
$299 to $449 a month at LillyDirect, medication only ($449 from 7.5 mg needs a refill within 45 days; otherwise $499 to $699). More on Zepbound cost without insurance.
Zepbound through a telehealth program
$448 to $598 a month at Ro, membership included.
Compounded tirzepatide at NexLife
$139 a month on a 12-month plan, or $169 month to month, at every dose, with your provider, nutrition plan and 24/7 support. Not FDA-approved. Here’s how a tirzepatide prescription works online.
Step by step
How do you choose between Zepbound, Mounjaro and compounded tirzepatide?
Zepbound and Mounjaro are both Lilly’s tirzepatide, with different approvals and prices; compounded tirzepatide isn’t a brand or FDA-approved. Here’s the order to weigh them in, with your provider.
- Start with what it’s approved for. Zepbound is approved for weight management, and sleep apnea in adults with obesity; Mounjaro for type 2 diabetes. Mounjaro isn’t FDA-approved for weight loss.
- Check your insurance. Coverage follows the approved use, so insurers often cover one brand and not the other. If your plan covers Zepbound, you pay your copay, usually after prior authorization.
- Compare self-pay prices. At LillyDirect, Zepbound is $299 to $449 a month by dose; the $449 from 7.5 mg needs a refill within 45 days, or it’s $499 to $699. Mounjaro is $499 a month at every dose (checked November 1, 2026).
- Know what compounded tirzepatide is. It isn’t a brand, and it isn’t FDA-approved; a licensed provider prescribes it only when it offers a significant difference for you. At NexLife, it’s $139 a month on the 12-month plan or $169 month to month.
- Let your provider decide, and use one at a time. Your provider decides what fits you. Zepbound’s label doesn’t recommend combining it with other tirzepatide products or any GLP-1 medicine, so don’t use two together.
Approval first, then coverage and price; your provider makes the final call.
Vial math
How many units is your tirzepatide dose?
It depends on your vial’s strength. Here are the label’s doses at one example strength, with the math to check your own.
| Dose | mL at 25 mg/mL | Units (U-100) | On the label |
|---|---|---|---|
| 2.5 mg | 0.1 mL | 10 units | Starting dose, for 4 weeks |
| 5 mg | 0.2 mL | 20 units | A maintenance dose |
| 7.5 mg | 0.3 mL | 30 units | A step up |
| 10 mg | 0.4 mL | 40 units | A maintenance dose |
| 12.5 mg | 0.5 mL | 50 units | A step up |
| 15 mg | 0.6 mL | 60 units | The maximum, and a maintenance dose |
The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units.
25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Read the strength on your own vial’s label; your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart.
What would you pay with NexLife?
Tap where you are now. We’ll show your NexLife price next to it, or tell you we’ll match it.
Pick one above to see your price.
Prices from each provider’s own site, checked November 1, 2026. Brand-name and compounded medications are different products: compounded medications aren’t FDA-approved, and a provider prescribes one only when it offers a significant difference for you. Price Match Guarantee† terms apply.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $139/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication
12-month plan $119/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Tirzepatide brand names: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
What is the brand name for tirzepatide?
Tirzepatide has two brand names, both from Eli Lilly. Zepbound is approved for weight management, and for sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes in adults and children 10 and older, and to lower the risk of major heart events in adults with type 2 diabetes at high risk.
Is Mounjaro the same as Zepbound?
Not exactly. Both are Eli Lilly’s brands of tirzepatide, weekly shots with matching dose strengths. But each is approved for different uses: Zepbound for weight management and sleep apnea, Mounjaro for type 2 diabetes. Don’t use them together; Zepbound’s label doesn’t recommend combining it with other tirzepatide products.
Is there a generic version of tirzepatide?
No. The FDA hasn’t approved one in the U.S., so Zepbound and Mounjaro are the only FDA-approved tirzepatide. Compounded tirzepatide doesn’t count: a state-licensed pharmacy prepares it for one patient’s prescription, and it isn’t FDA-approved. Foundayo (orforglipron), Lilly’s
Who makes tirzepatide?
Eli Lilly and Company makes both brand-name versions, Zepbound and Mounjaro, and sells them at self-pay prices through LillyDirect. Compounded tirzepatide is different: a state-licensed pharmacy prepares it for one patient’s prescription, and it isn’t FDA-approved. At NexLife, partner pharmacies fill each prescription; NexLife doesn’t make or compound medication.
Can I get Mounjaro for weight loss?
Mounjaro isn’t FDA-approved for weight loss. It’s approved for type 2 diabetes in adults and children 10 and older, and to lower the risk of major heart events in adults with type 2 diabetes at high risk. Prescribing it for weight loss is off-label; the FDA-approved tirzepatide for weight management is Zepbound. Your provider decides what fits you.
How much is brand-name tirzepatide without insurance?
LillyDirect’s self-pay prices, checked November 1, 2026: Zepbound is $299 at 2.5 mg, $399 at 5 mg and $449 a month from 7.5 mg; Mounjaro is $499 a month at every dose. Zepbound’s $449 needs a refill within 45 days, or it’s $499 to $699. Compounded tirzepatide at NexLife is $139 a month on the 12-month plan.
What’s the difference between Zepbound and Mounjaro?
The approval, and the price. Both are Lilly’s tirzepatide at matching weekly doses, but Zepbound is approved for weight management and sleep apnea, and Mounjaro for type 2 diabetes. At LillyDirect, Mounjaro is $499 a month at every dose; Zepbound starts at $299 at 2.5 mg (checked November 1, 2026). Insurance coverage follows the approved use.
What is the Zepbound KwikPen?
A pen that holds four weekly doses of Zepbound, so one pen covers four weeks. It comes in the same six strengths as the single-dose pens, from 2.5 mg to 15 mg. Through LillyDirect, it starts at $299 a month at 2.5 mg (checked November 1, 2026). Mounjaro also comes as a 4-dose KwikPen.
What is the generic price of tirzepatide?
There isn’t one: the FDA hasn’t approved any tirzepatide besides Lilly’s Zepbound and Mounjaro. Zepbound is $299 to $449 a month at LillyDirect, by dose (checked November 1, 2026); the $449 from 7.5 mg needs a refill within 45 days, or it’s $499 to $699. Compounded tirzepatide isn’t FDA-approved; at NexLife, it’s $139 a month on the 12-month plan.
Is there a tirzepatide pill?
Not an FDA-approved one. Tirzepatide’s brand names, Zepbound and Mounjaro, are both weekly shots from 2.5 mg to 15 mg, and no other version is FDA-approved. Foundayo (orforglipron), Lilly’s GLP-1 pill approved in 2026, is a different medicine, not tirzepatide.
Is compounded tirzepatide a brand-name drug?
No. Compounded tirzepatide isn’t a brand, and it isn’t FDA-approved: a state-licensed pharmacy prepares it for one patient’s prescription. A licensed provider prescribes it only when it offers a significant difference for you. At NexLife, it’s $139 a month on the 12-month plan or $169 month to month.
Does Zepbound come in vials or pens?
Both. Zepbound comes as single-dose pens and vials, 4-dose vials and the 4-dose KwikPen. Mounjaro comes the same ways, and each is a weekly shot from 2.5 mg to 15 mg. Through LillyDirect, the Zepbound KwikPen starts at $299 a month at 2.5 mg (checked November 1, 2026).
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
“No. A generic drug is approved by FDA under 505(j) of the FD&C Act and meets all of the requirements of that section (including establishing therapeutic equivalence to a brand name drug, among others), while a compounded drug is not approved by FDA.”
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Checked the Zepbound and Mounjaro labels, LillyDirect’s self-pay prices and the FDA approval of Foundayo.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
Paying less elsewhere? We match it.†
Prefer one flat price? $139 a month on 12 months at every dose.
$139 a month on a 12-month plan, or $169 month to month. About 3 minutes of health questions. A licensed provider decides if tirzepatide is right for you.
4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information.
- Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information.
- Eli Lilly and Company. Zepbound through LillyDirect.
- AJMC. FDA approves monthly KwikPen option for tirzepatide in chronic weight management (February 23, 2026).
- Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), news release (April 1, 2026).
- Ro. Weight loss pricing (Zepbound and Wegovy self-pay prices).
- U.S. Food and Drug Administration. FDA’s concerns with unapproved
GLP-1 drugs used for weight loss. - NexLife. Compounded tirzepatide plans.
- Novo Nordisk. Wegovy (semaglutide) prescribing information.
- LegitScript. LegitScript certification record for NexLife.us.
- NexLife. Compounded semaglutide plans.
- Ro: weight loss program pricing. Checked November 1, 2026.
- Hims: Zepbound KwikPen. Checked November 1, 2026.
- Hims: Wegovy pill and pen, with membership. Checked November 1, 2026.
- Mochi Health: FAQs (membership and medication prices). Checked November 1, 2026.
- Embody: compounded tirzepatide, one-month supply. Checked November 1, 2026.
- Embody: compounded semaglutide, one-month supply. Checked November 1, 2026.
- Eli Lilly and Company: Mounjaro (tirzepatide) prescribing information, revised August 2026 (indications and dosage forms). Read November 1, 2026.
- Eli Lilly and Company: Mounjaro through LillyDirect (self-pay prices). Checked November 1, 2026.
- Eli Lilly and Company, on Drugs@FDA. Zepbound (tirzepatide) prescribing information, revised February 2026 (FDA’s copy). Read November 2, 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Read November 2, 2026.